Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Profound Medical ( (TSE:PRN) ) just unveiled an announcement.
Profound Medical Corp. announced the successful pricing and closure of an underwritten public offering of 4,666,700 common shares at $7.50 per share, with an over-allotment option fully exercised, raising gross proceeds of approximately $40.25 million. The funds will be used to further commercialize its TULSA-PRO® and Sonalleve® systems globally, and support general corporate purposes, strengthening its market position and operational capabilities.
More about Profound Medical
Profound Medical Corp. operates in the medical technology industry, focusing on the development and commercialization of innovative therapeutic systems. Its primary products include the TULSA-PRO® system and the Sonalleve® system, which are utilized for precision ablation of diseased tissue, aimed at enhancing patient outcomes in various medical procedures.
YTD Price Performance: -4.86%
Average Trading Volume: 8,968
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$260.4M
For a thorough assessment of PRN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue